⦁ Accurate diagnosis of cancers with high FGF19 levels with poor prognosis (e.g., HCC).
⦁ Incorporation into personalized medical diagnosis of cancer will enable selection of optimal therapeutic agents such as Lenvatinib.
Technology & Background
It has been reported that hepatocellular carcinoma (HCC) with high FGF19 production is associated with high malignancy, early postoperative recurrence, and poor prognosis. Since HCC is diagnosed by imaging studies such as CT/MRI and therapeutic intervention is performed, it is difficult to identify the expression and extent of FGF19 in HCC prior to treatment. Lenvatinib and other drugs targeting the FGF19/FGFR4 pathway have been developed for HCC and other cancer with high FGF19 production. However, there are no biomarkers to predict the efficacy of these drugs, and no stratified treatment strategy has been established.
The inventors searched for factors that alter expression levels in conjunction with FGF19 in tumor cells. As a result, it was found that tumor-derived secreted proteins downstream of the FGF19/FGFR4 pathway, such as “ST6GAL1”, are useful as serum biomarkers for estimating the expression level of FGF19 in HCC and the drug sensitivity of FGF19/FGFR4-targeting drugs (see below: for details, please refer to the following the publishment).
⦁ ROC curve for the diagnosis of HCC patients with elevated FGF19 by serum ST6GAL1 level
⦁ Survival of Patients with HCC in the High Serum ST6GAL1 Group (34 patients) Treated with Either Lenvatinib or Sorafenib
Researchers & Academic Institution
Dr. Takahiro KODAMA (Osaka University Graduate School of Medicine)
Applied in Japan. (Before PCT-phase)
Y. Myojin, T. Kodama, et al. Clin. Cancer. Res. 2021; 27:1150-1161.
Tech Manage Corp. is now looking for companies that are interested in developing ST6GAL1 as a therapeutic drug selection marker for cancer. Collaborative research on the development of new drug selection markers based on the developed mouse model is also welcome.